secwatch.observer — SEC 8-K summary
======================================

Issuer:     BullFrog AI Holdings, Inc. (BFRG)
CIK:        0001829247
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001493152-24-002348
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BullFrog AI receives Australian patent for mebendazole prodrugs including BF-223
--------------------------------------------------------------------------------

- Australian Patent No. 2019216757 issued for novel prodrugs of mebendazole to treat cancers.
- Follows U.S. Patent No. 11,712,435 issued July 2023; additional territories expected.
- Patented compounds show improved solubility and oral bioavailability versus parent mebendazole.
- BF-223, a key pipeline asset, previously showed anticancer activity in a glioblastoma animal model.
- CEO Vin Singh says patent strengthens IP protection and supports partnering strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829247/000149315224002348/0001493152-24-002348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829247/000149315224002348/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-002348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer